OncoTargets and Therapy (Oct 2019)
Perioperative Targeted Therapy Or Immunotherapy In Non-Small-Cell Lung Cancer
Abstract
Huanlan Sa,1,* Peng Song,2,* Kewei Ma,3 Yong Gao,1 Li Zhang,2 Deqiang Wang1 1Department of Pain Management, Affiliated Hospital of Binzhou Medical University, Binzhou 256603, People’s Republic of China; 2Department of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100010, People’s Republic of China; 3Department of Oncology, Cancer Center, The First Hospital of Jilin University, Changchun, 130021, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li ZhangDepartment of Respiratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, People’s Republic of ChinaTel +8618811630866Email [email protected] WangDepartment of Pain Management, Affiliated Hospital of Binzhou Medical University, Binzhou 256603, People’s Republic of ChinaTel +8615066918983Email [email protected]: Targeted therapy and immunotherapy have changed the treatment modes for advanced non-small cell lung cancer (NSCLC), moving from second-line to first-line treatment and significantly extending patients’ survival. Surgery and chemoradiotherapy remain the main treatment options for patients with locally advanced lung cancer, but recurrence and metastasis still occur in some patients. The survival rates of conventional perioperative chemotherapy among NSCLC patients have increased by only 5%. Therefore, more studies have begun to explore targeted and immune neoadjuvant/adjuvant therapies in early-stage and locally advanced NSCLC, and the relevant clinical research data have shown good efficacy and safety profiles. This article summarizes several clinical studies of critical importance.Keywords: non-small-cell lung cancer, targeted therapy, immunotherapy
